Gilead’s GS9450 falters in hepatitis C, but HIV combo component advances
This article was originally published in Scrip
Gilead has unexpectedly halted a Phase II trial of its investigational caspase inhibitor GS9450 in patients with chronic hepatitis C due to safety concerns. The company tried to temper the unexpected news by emphasizing that Johnson & Johnson's NNRTI TMC278 (rilpivirine hydrochloride), which is being developed in part to be combined with Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate), met its primary endpoints in two pivotal Phase III HIV trials, but analysts were divided on the implications of this development.
You may also be interested in...
Experimental drugs rarely face setbacks because they are too effective, but Pfizer's novel nerve growth factor antagonist tanezumab might number among the unlucky few. Phase II data presented this week in the NEJM show that the monoclonal antibody relieved osteoarthritic pain, but an accompanying editorial proposed that in doing so the analgesic enables physical activity that can lead to excessive wear and tear on fragile joints.
AstraZeneca has enrolled the first patient in the pivotal programme for the first-in-class Syk kinase inhibitor fostamatinib (previously known as R778). Fostamatinib, which it licensed from Rigel Pharmaceuticals, is being evaluated as a treatment for rheumatoid arthritis (RA) in patients with an inadequate response to disease modifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX).
The Michael J. Fox foundation has launched a $40 million, 5-year initiative to identify biomarkers of Parkinson's disease progression. The scheme, called the Parkinson's Progression Markers Initiative (PPMI), will be carried out at 18 sites in the US and the EU, and will track 400 patients with newly diagnosed disease as well as 200 who do not have the disease.